tradingkey.logo

Aclarion Inc

ACON
5.880USD
-0.110-1.84%
收盘 12/24, 13:00美东报价延迟15分钟
3.42M总市值
亏损市盈率 TTM

Aclarion Inc

5.880
-0.110-1.84%

关于 Aclarion Inc 公司

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Aclarion Inc简介

公司代码ACON
公司名称Aclarion Inc
上市日期Apr 22, 2022
CEONess (Brent)
员工数量6
证券类型Ordinary Share
年结日Apr 22
公司地址8181 Arista Place
城市BROOMFIELD
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编80021
电话18332752266
网址https://aclarion.com/
公司代码ACON
上市日期Apr 22, 2022
CEONess (Brent)

Aclarion Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.00
+333.33%
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.00
+333.33%
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月21日 周五
更新时间: 11月21日 周五
持股股东
股东类型
持股股东
持股股东
占比
DRW Securities, LLC
1.72%
CAPTRUST Financial Advisors
1.49%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.31%
Tower Research Capital LLC
0.09%
其他
95.38%
持股股东
持股股东
占比
DRW Securities, LLC
1.72%
CAPTRUST Financial Advisors
1.49%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.31%
Tower Research Capital LLC
0.09%
其他
95.38%
股东类型
持股股东
占比
Investment Advisor
4.22%
Investment Advisor/Hedge Fund
0.31%
Hedge Fund
0.09%
Research Firm
0.04%
其他
95.35%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
15
31.25K
1.59%
--
2025Q3
15
31.25K
0.88%
+26.14K
2025Q2
9
2.11K
0.08%
+1.65K
2025Q1
16
366.00
0.00%
+366.00
2024Q4
14
--
0.00%
--
2024Q3
14
--
0.00%
--
2024Q2
21
--
0.00%
--
2024Q1
22
--
0.00%
--
2023Q4
21
--
0.00%
--
2023Q3
20
--
0.00%
--
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
1.71K
0.29%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
1.59K
0.27%
+610.00
+62.37%
Aug 31, 2025
Tower Research Capital LLC
75.00
0.01%
+72.00
+2400.00%
Jun 30, 2025
Ness (Brent)
3.00
0%
+3.00
--
May 09, 2025
Thramann (Jeffrey John)
10.00
0%
+10.00
--
May 09, 2025
BofA Global Research (US)
8.00
0%
+4.00
+100.00%
Jun 30, 2025
Clear Street LLC
3.00
0%
--
--
Jun 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
公告日期
类型
比率
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 02, 2024
Merger
16→1
Jan 02, 2024
Merger
16→1
查看更多

常见问题

Aclarion Inc的前五大股东是谁?

Aclarion Inc 的前五大股东如下:
The Vanguard Group, Inc.持有股份:1.71K,占总股份比例:0.29%。
Geode Capital Management, L.L.C.持有股份:1.59K,占总股份比例:0.27%。
Tower Research Capital LLC持有股份:75.00,占总股份比例:0.01%。
Ness (Brent)持有股份:3.00,占总股份比例:0.00%。
Thramann (Jeffrey John)持有股份:10.00,占总股份比例:0.00%。

Aclarion Inc的前三大股东类型是什么?

Aclarion Inc 的前三大股东类型分别是:
DRW Securities, LLC
CAPTRUST Financial Advisors
The Vanguard Group, Inc.

有多少机构持有Aclarion Inc(ACON)的股份?

截至2025Q4,共有15家机构持有Aclarion Inc的股份,合计持有的股份价值约为31.25K,占公司总股份的1.59%。与2025Q3相比,机构持股有所增加,增幅为0.71%。

哪个业务部门对Aclarion Inc的收入贡献最大?

在--,--业务部门对Aclarion Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI